Teva Pharmaceutical Industries Ltd Company Profile (NYSE:TEVA)

About Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd logoTeva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NYSE:TEVA
  • CUSIP: N/A
  • Web: www.tevapharm.com
Capitalization:
  • Market Cap: $28.96 billion
  • Outstanding Shares: 1,016,000,000
Average Prices:
  • 50 Day Moving Avg: $31.13
  • 200 Day Moving Avg: $34.26
  • 52 Week Range: $28.06 - $56.44
P/E:
  • Trailing P/E Ratio: 368.08
  • Foreward P/E Ratio: 6.06
  • P/E Growth: 2.15
Sales & Book Value:
  • Annual Revenue: $22.72 billion
  • Price / Sales: 1.27
  • Book Value: $29.92 per share
  • Price / Book: 0.95
Dividend:
  • Annual Dividend: $1.16
  • Dividend Yield: 4.7%
Profitability:
  • EBIDTA: $7.32 billion
  • Net Margins: 1.50%
  • Return on Equity: 17.46%
  • Return on Assets: 7.32%
Debt:
  • Debt-to-Equity Ratio: 0.99%
  • Current Ratio: 0.90%
  • Quick Ratio: 0.62%
Misc:
  • Average Volume: 6.94 million shs.
  • Beta: 0.58
  • Short Ratio: 2.43
 

Frequently Asked Questions for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

What is Teva Pharmaceutical Industries Ltd's stock symbol?

Teva Pharmaceutical Industries Ltd trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries Ltd pay dividends? What is the dividend yield for Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd announced a quarterly dividend on Thursday, May 11th. Investors of record on Monday, June 5th will be paid a dividend of $0.34 per share on Thursday, June 22nd. This represents a $1.36 dividend on an annualized basis and a yield of 4.77%. The ex-dividend date of this dividend is Thursday, June 1st. View Teva Pharmaceutical Industries Ltd's Dividend History.

How were Teva Pharmaceutical Industries Ltd's earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) posted its earnings results on Thursday, May, 11th. The company reported $1.06 EPS for the quarter, hitting analysts' consensus estimates of $1.06. The company earned $5.63 billion during the quarter, compared to the consensus estimate of $5.69 billion. Teva Pharmaceutical Industries Ltd had a net margin of 1.50% and a return on equity of 17.46%. The company's revenue was up 17.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.20 EPS. View Teva Pharmaceutical Industries Ltd's Earnings History.

What guidance has Teva Pharmaceutical Industries Ltd issued on next quarter's earnings?

Teva Pharmaceutical Industries Ltd updated its FY17 earnings guidance on Thursday, May, 11th. The company provided earnings per share (EPS) guidance of $4.90-5.30 for the period, compared to the Thomson Reuters consensus estimate of $4.81. The company issued revenue guidance of $23.8-24.5 billion, compared to the consensus revenue estimate of $23.67 billion.

Where is Teva Pharmaceutical Industries Ltd's stock going? Where will Teva Pharmaceutical Industries Ltd's stock price be in 2017?

25 brokers have issued twelve-month price targets for Teva Pharmaceutical Industries Ltd's shares. Their predictions range from $25.00 to $80.00. On average, they anticipate Teva Pharmaceutical Industries Ltd's stock price to reach $44.43 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries Ltd.

What are analysts saying about Teva Pharmaceutical Industries Ltd stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries Ltd stock:

  • 1. According to Zacks Investment Research, "The Actavis Generics acquisition helped Teva strengthen its position in the key generic markets. Teva continues to progress with its branded and generics drugs pipeline and is looking to strengthen its biosimilar pipeline. Meanwhile, Teva intends to accelerate growth platforms, protect and expand core franchises, expand its global presence, pursue strategic deals and reduce the cost base. However, headwinds remain in the form of generic competition for Copaxone, new competition for branded products, fewer large generic opportunities, generic pricing pressure, a higher cost base and debt level and the sudden departure of its chief executive office. Also, Teva’s shares underperformed the generic industry in the past one  year.  Estimate movement has been mixed ahead of the company’s Q1 earnings release. The company has a positive record of earnings surprises in recent quarters. " (4/17/2017)
  • 2. Maxim Group analysts commented, "We reviewed and revised our model prior to the 1Q17 earnings release. Based on 2017 guidance and our expectations, we adjust OTC revenues in 1Q17 to $277M from $346M to reflect the change in foreign exchange rate as of December 1, 2016. Our estimate for total 2017 revenues is unchanged at $24B." (3/29/2017)
  • 3. Royal Bank of Canada analysts commented, "TEVA reported 4Q above Street expectations and reaffirmed 2017 guidance with some further color around the year. The bull case in TEVA lacks conviction and change is needed. We look to CEO search/ strategic review, potential for break-up, and potential upside from generic Copaxone surprise as opportunity but near-term confidence remains low. No change to PT but EPS moves lower to reflect greater competitive pressures." (2/14/2017)

Who are some of Teva Pharmaceutical Industries Ltd's key competitors?

Who owns Teva Pharmaceutical Industries Ltd stock?

Teva Pharmaceutical Industries Ltd's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (3.62%), Barrow Hanley Mewhinney & Strauss LLC (2.93%), Bank of New York Mellon Corp (1.91%), Nordea Investment Management AB (1.24%), Paulson & CO. Inc. (1.08%) and Alliancebernstein L.P. (0.85%). View Institutional Ownership Trends for Teva Pharmaceutical Industries Ltd.

Who sold Teva Pharmaceutical Industries Ltd stock? Who is selling Teva Pharmaceutical Industries Ltd stock?

Teva Pharmaceutical Industries Ltd's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Lazard Asset Management LLC, Paulson & CO. Inc., Henderson Group PLC, Janus Capital Management LLC, Barrow Hanley Mewhinney & Strauss LLC, Waddell & Reed Financial Inc. and NN Investment Partners Holdings N.V.. View Insider Buying and Selling for Teva Pharmaceutical Industries Ltd.

Who bought Teva Pharmaceutical Industries Ltd stock? Who is buying Teva Pharmaceutical Industries Ltd stock?

Teva Pharmaceutical Industries Ltd's stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Harel Insurance Investments & Financial Services Ltd., Ameriprise Financial Inc., Commerzbank Aktiengesellschaft FI, Private Management Group Inc., State Street Corp, Alliancebernstein L.P. and Teachers Retirement System of The State of Kentucky. View Insider Buying and Selling for Teva Pharmaceutical Industries Ltd.

How do I buy Teva Pharmaceutical Industries Ltd stock?

Shares of Teva Pharmaceutical Industries Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Teva Pharmaceutical Industries Ltd stock cost?

One share of Teva Pharmaceutical Industries Ltd stock can currently be purchased for approximately $28.50.

Analyst Ratings

Consensus Ratings for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (?)
Ratings Breakdown: 1 Sell Rating, 11 Hold Ratings, 13 Buy Ratings
Consensus Rating:Hold (Score: 2.48)
Consensus Price Target: $44.43 (55.90% upside)

Analysts' Ratings History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017MizuhoLower Price TargetUnderperform$29.00 -> $25.00LowView Rating Details
5/17/2017Credit Suisse Group AGReiterated RatingBuy$39.00HighView Rating Details
5/15/2017Royal Bank of CanadaReiterated RatingOutperform$42.00 -> $38.00LowView Rating Details
5/12/2017Deutsche Bank AGLower Price TargetBuy$45.00 -> $43.00LowView Rating Details
5/11/2017Maxim GroupSet Price TargetHold$35.00LowView Rating Details
4/29/2017Wells Fargo & CoReiterated RatingMarket PerformLowView Rating Details
4/25/2017Citigroup IncLower Price TargetBuy$47.00 -> $42.00HighView Rating Details
4/7/2017CIBCReiterated RatingBuy$43.00LowView Rating Details
4/6/2017Oppenheimer Holdings Inc.Set Price TargetBuy$43.00LowView Rating Details
4/6/2017BTIG ResearchReiterated RatingNeutralLowView Rating Details
4/4/2017Cowen and CompanyReiterated RatingOutperform$50.00LowView Rating Details
3/16/2017Jefferies Group LLCSet Price TargetHold$33.00LowView Rating Details
2/28/2017ArgusDowngradeBuy -> Hold$59.35 -> $31.90N/AView Rating Details
2/24/2017Sanford C. BernsteinReiterated RatingOutperform$42.00N/AView Rating Details
2/17/2017JPMorgan Chase & Co.Set Price TargetHold$37.00N/AView Rating Details
1/31/2017Barclays PLCLower Price TargetEqual Weight$46.00 -> $38.00N/AView Rating Details
1/31/2017Bank of America CorpUpgradeNeutral -> BuyN/AView Rating Details
1/9/2017GabelliReiterated RatingBuyN/AView Rating Details
12/23/2016GuggenheimReiterated RatingBuy$80.00N/AView Rating Details
12/4/2016Morgan StanleyDowngradeOverweight -> Equal Weight$63.00 -> $42.00N/AView Rating Details
11/4/2016HSBC Holdings plcDowngradeBuy -> Hold$44.00 -> $66.00N/AView Rating Details
10/7/2016Leerink SwannSet Price TargetBuy$57.00N/AView Rating Details
9/29/2016OTR GlobalInitiated CoveragePositiveN/AView Rating Details
8/8/2016Piper Jaffray CompaniesReiterated RatingNeutral$55.00 -> $57.00N/AView Rating Details
7/17/2016Goldman Sachs Group IncLower Price Target$70.00 -> $60.00N/AView Rating Details
4/19/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
3/2/2016NomuraReiterated RatingNeutral$73.00N/AView Rating Details
11/27/2015Berenberg BankLower Price TargetHold$72.00 -> $65.00N/AView Rating Details
7/28/2015BMO Capital MarketsUpgradeMarket Perform -> Outperform$75.00 -> $80.00N/AView Rating Details
7/27/2015Standpoint ResearchBoost Price TargetBuy$78.00 -> $84.00N/AView Rating Details
6/3/2015Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Earnings by Quarter for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Earnings History by Quarter for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 17$1.06$1.06$5.69 billion$5.63 billionViewN/AView Earnings Details
2/13/2017Q416$1.36$1.38$6.26 billion$6.25 billionViewN/AView Earnings Details
11/15/2016Q316$1.29$1.31$5.71 billion$5.56 billionViewN/AView Earnings Details
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Current Year EPS Consensus Estimate: $4.78 EPS
Next Year EPS Consensus Estimate: $4.70 EPS

Dividends

Current Dividend Information for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Next Dividend:6/22/2017
Annual Dividend:$1.16
Dividend Yield:4.07%
Dividend Growth:2.10% (3 Year Average)
Payout Ratio:1,657.38% (Trailing 12 Months of Earnings)
24.27% (Based on This Year's Estimates)
24.68% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Dividend History by Quarter for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/11/2017quarterly$0.344.28%6/1/20176/5/20176/22/2017
2/13/2017quarterly$0.343.7%2/28/20173/2/20173/20/2017
11/15/2016quarterly$0.3412/1/201612/5/201612/20/2016
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.292/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.322.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.352.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.352.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.333.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.323.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.328/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Latest Headlines for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Source:
DateHeadline
investorplace.com logoWhy Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Could Gain 30%
investorplace.com - May 26 at 12:10 PM
reuters.com logoTeva to pay $1.6 million to resolve California counties' opioid case - Reuters
www.reuters.com - May 26 at 7:40 AM
americanbankingnews.com logoMizuho Reiterates "Underperform" Rating for Teva Pharmaceutical Industries Ltd (TEVA)
www.americanbankingnews.com - May 25 at 7:27 PM
nasdaq.com logoTeva Pharmaceutical Industries Enters Oversold Territory - Nasdaq
www.nasdaq.com - May 25 at 4:41 AM
investorplace.com logoWhy Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Going to $40 - Investorplace.com
investorplace.com - May 25 at 4:41 AM
americanbankingnews.com logoStock Traders Buy High Volume of Teva Pharmaceutical Industries Put Options (TEVA)
www.americanbankingnews.com - May 24 at 12:26 PM
investorplace.com logoWhy Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Going to $40
investorplace.com - May 24 at 10:32 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Teva and Cerus Corporation
finance.yahoo.com - May 24 at 8:55 AM
investopedia.com logoTeva Breaks Down to Fresh Lows – Will It Bottom Out? (TEVA)
www.investopedia.com - May 23 at 7:34 PM
finance.yahoo.com logoTeva Reaches New Lows – Will It Bottom Out?
finance.yahoo.com - May 23 at 7:34 PM
americanbankingnews.com logoVetr Inc. Lowers Teva Pharmaceutical Industries Ltd (TEVA) to Buy
www.americanbankingnews.com - May 22 at 10:20 PM
seekingalpha.com logoTeva: What's Going On? - Seeking Alpha
seekingalpha.com - May 22 at 8:38 AM
finance.yahoo.com logo3 Drug Stocks Billionaire Money Managers Dumped Big-Time in the First Quarter
finance.yahoo.com - May 22 at 8:38 AM
finance.yahoo.com logoVetr Issues Strong Buy As Teva Trends Down
finance.yahoo.com - May 19 at 1:05 PM
finance.yahoo.com logoValeant (VRX) Decides to Extend Stay on Xifaxan's ANDA
finance.yahoo.com - May 19 at 1:05 PM
finance.yahoo.com logoTeva Pharmaceutical's search committee recommends foreign CEO: report
finance.yahoo.com - May 18 at 12:45 PM
finance.yahoo.com logoTeva Pharmaceutical Leaning Towards Foreigner as New CEO
finance.yahoo.com - May 18 at 12:45 PM
americanbankingnews.com logoTeva Pharmaceutical Industries Ltd (TEVA) Upgraded at Vetr Inc.
www.americanbankingnews.com - May 18 at 12:21 AM
businesswire.com logoTeva Showcases Asthma Research at the 2017 American Thoracic Society (ATS) International Conference - Business Wire (press release)
www.businesswire.com - May 17 at 8:08 PM
americanbankingnews.com logoTeva Pharmaceutical Industries Ltd (TEVA) Stock Rating Reaffirmed by Credit Suisse Group AG
www.americanbankingnews.com - May 17 at 5:16 PM
finance.yahoo.com logoTeva to Present Data for Deutetrabenazine in Tardive Dyskinesia at the American Psychiatric Association 2017 Annual Meeting
finance.yahoo.com - May 17 at 11:42 AM
finance.yahoo.com logoTeva Showcases Asthma Research at the 2017 American Thoracic Society (ATS) International Conference
finance.yahoo.com - May 17 at 11:42 AM
businesswire.com logoTeva Announces Launch of Generic Glumetza® in the United States ... - Business Wire (press release)
www.businesswire.com - May 16 at 11:45 AM
finance.yahoo.com logoTeva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka
finance.yahoo.com - May 16 at 11:45 AM
bizjournals.com logoTeva launches generic diabetes drug - Philadelphia Business Journal
www.bizjournals.com - May 15 at 3:51 PM
investorplace.com logoWhy Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Can Recover - Investorplace.com
investorplace.com - May 15 at 3:51 PM
finance.yahoo.com logoTeva Announces Launch of Generic Glumetza® in the United States
finance.yahoo.com - May 15 at 3:51 PM
investorplace.com logoWhy Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Can Recover
investorplace.com - May 15 at 2:27 PM
americanbankingnews.com logoTeva Pharmaceutical Industries Ltd (TEVA) Receives Outperform Rating from Royal Bank of Canada
www.americanbankingnews.com - May 15 at 12:26 PM
businesswire.com logoOtsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV ... - Business Wire (press release)
www.businesswire.com - May 15 at 8:59 AM
finance.yahoo.com logoBiostime International Holdings Limited -- Moody's: Biostime's ratings unaffected by disclosure of PGT option in collaboration agreement with Swisse
finance.yahoo.com - May 15 at 8:59 AM
finance.yahoo.com logoOtsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)
finance.yahoo.com - May 15 at 8:59 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Ltd (TEVA) PT Set at $35.00 by Maxim Group
www.americanbankingnews.com - May 13 at 6:58 PM
americanbankingnews.com logoTeva Pharmaceutical Industries Sees Unusually High Options Volume (TEVA)
www.americanbankingnews.com - May 13 at 7:44 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Teva Pharmaceuticals and Merck & Co.
finance.yahoo.com - May 13 at 1:43 AM
finance.yahoo.com logoHere's How Much Teva Pharmaceutical Could Net From the Sale of Non-Core Assets
finance.yahoo.com - May 13 at 1:43 AM
fool.com logoActavis Generics Acquisition Drives Teva Pharmaceutical Industries Ltd. First-Quarter Sales Higher - Motley Fool
www.fool.com - May 12 at 3:40 PM
americanbankingnews.com logoTeva Pharmaceutical Industries Ltd (TEVA) Given "Buy" Rating at Deutsche Bank AG
www.americanbankingnews.com - May 12 at 11:04 AM
nasdaq.com logoTeva Pharmaceutical Industries Limited Announces 8% Drop In Q1 Profit
www.nasdaq.com - May 12 at 2:16 AM
seekingalpha.com logoTeva Pharmaceutical Industries Limited 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 12 at 2:16 AM
finance.yahoo.com logoTeva to Sell Assets Such as Women's Health Unit to Cut Debt
finance.yahoo.com - May 12 at 2:16 AM
finance.yahoo.com logoTeva (TEVA) Q1 Earnings In-Line, Sales Miss, Shares Up
finance.yahoo.com - May 12 at 2:16 AM
finance.yahoo.com logoTEVA's Every Narrowing Margin for Error
finance.yahoo.com - May 12 at 2:16 AM
finance.yahoo.com logoTeva Pharma Q1 Sales Lag As Key Multiple Sclerosis Drug Topples
finance.yahoo.com - May 12 at 2:16 AM
finance.yahoo.com logo[$$] Investors Are Losing Patience With Teva
finance.yahoo.com - May 12 at 2:16 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Ltd to Issue Quarterly Dividend of $0.34 (TEVA)
www.americanbankingnews.com - May 11 at 2:20 PM
americanbankingnews.com logo$1.03 EPS Expected for Teva Pharmaceutical Industries Ltd (TEVA) This Quarter
www.americanbankingnews.com - May 11 at 2:14 PM
americanbankingnews.com logoTeva Pharmaceutical Industries Ltd (TEVA) Issues Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - May 11 at 1:52 PM
fool.com logoActavis Generics Acquisition Drives Teva Pharmaceutical Industries Ltd. First-Quarter Sales Higher
www.fool.com - May 11 at 1:17 PM
americanbankingnews.com logoTeva Pharmaceutical Industries Ltd (TEVA) Issues FY17 Earnings Guidance
www.americanbankingnews.com - May 11 at 9:30 AM

Social

Chart

Teva Pharmaceutical Industries Ltd (TEVA) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff